Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir by Year
Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir: $25M in FY2019, up 78.6% from a year earlier. No newer figure appears in the documents we track.
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-25) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 25 | +78.6% | Form 10-K (filed 2020-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 14 | +250.0% | Form 10-K (filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 4 | – | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Vosevi (sofosbuvir / velpatasvir / voxilaprevir ($M), annual FY2016–FY2019 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-vosevi-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.